Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 8:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 13,479 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: cGVHD Clear all
Completed Phase 1 Interventional

Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

NCT07342868
View directory record Official record
Conditions
Chronic Hepatitis B Infections
Interventions
Pevifoscorvir Sodium (ALG-000184)
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 26, 2026, 8:16 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

NCT00300274
View directory record Official record
Conditions
Graft Rejection
Interventions
everolimus, mycophenolate mofetil, cyclosporine, corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Oct 26, 2026, 8:16 AM EDT
Terminated Phase 4 Interventional

Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain

NCT00904397
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Lidoderm®, Celecoxib
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
21
States / cities
Northport, Alabama • Phoenix, Arizona • Beverly Hills, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2010 · Synced Oct 26, 2026, 8:16 AM EDT
Recruiting Phase 3 Interventional

CARES (Comprehensive Analgesic, Recovery, and Education Support) for Surgery Trial

NCT06027099
View directory record Official record
Conditions
Chronic Pain, Back Pain, Neck Pain, Opioid Misuse
Interventions
Tizanidine, MI-Opioid Taper, Placebo, Enhanced Usual Care
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Stanford, California • Kansas City, Kansas • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 26, 2026, 8:16 AM EDT
Completed Phase 1 Interventional

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

NCT01702064
View directory record Official record
Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
Nilotinib, Ruxolitinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 26, 2026, 8:16 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

NEAT!2 Sedentary Behavior Reduction for Individuals With Past or Present Knee Symptoms, Injuries, or Surgeries

NCT03987932
View directory record Official record
Conditions
Sedentary Lifestyle, Knee Osteoarthritis, Knee Injuries, Knee Pain Chronic
Interventions
NEAT!2, NEAT!2+Calls, Delayed NEAT!2
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
40 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 26, 2026, 8:16 AM EDT
Completed No phase listed Observational Results available

ClotTriever Outcomes (CLOUT) Registry

NCT03575364
View directory record Official record
Conditions
Deep Vein Thrombosis Leg, DVT, Chronic DVT of Lower Extremity, Acute DVT of Lower Extremity
Interventions
ClotTriever
Device
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
43
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 26, 2026, 8:16 AM EDT
Completed Not applicable Interventional

Post-stroke Perturbation Training

NCT04855032
View directory record Official record
Conditions
Stroke
Interventions
Reactive Perturbations, Proactive Perturbations
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 26, 2026, 8:16 AM EDT
Recruiting Not applicable Interventional

The HEARTFELT Study

NCT06222099
View directory record Official record
Conditions
Heart Failure, Chronic Heart Failure
Interventions
Heartfelt Device installed, Standard care, Heartfelt-guided care, Questionnaires
Device · Other
Lead sponsor
Heartfelt Technologies
Industry
Eligibility
22 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Little Rock, Arkansas • Hackensack, New Jersey • Bala-Cynwyd, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 26, 2026, 8:16 AM EDT
Terminated Phase 4 Interventional Results available

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

NCT03226899
View directory record Official record
Conditions
Gout, Chronic Kidney Disease (CKD)
Interventions
Lesinurad, XOI, Placebo, colchicine, corticosteroids
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
70
States / cities
Birmingham, Alabama • Tucson, Arizona • Covina, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 26, 2026, 8:16 AM EDT
Completed Phase 4 Interventional Results available

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

NCT00735787
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Bakersfield, California • Macon, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2010 · Synced Oct 26, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase

NCT00084916
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes
Interventions
temsirolimus, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 26, 2026, 8:16 AM EDT
Completed Phase 4 Interventional

Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma

NCT01241006
View directory record Official record
Conditions
Asthma, Reactive Airway Disease
Interventions
Dexamethasone, Prednisone
Drug
Lead sponsor
Alameda County Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Oct 26, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)

NCT00559052
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency
Interventions
VIOKASE 16
Drug
Lead sponsor
Axcan Pharma
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Gainesville, Florida • Mayo Clinic- Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Oct 26, 2026, 8:16 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of Nutrition in Maintenance Hemodialysis Patients

NCT02917278
View directory record Official record
Conditions
End-Stage Renal Disease, Meals, Hemodialysis
Interventions
Meals
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 26, 2026, 8:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00244985
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, pegylated liposomal doxorubicin hydrochloride
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 26, 2026, 8:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain, Brainstem, and Spinal Cord fMRI

NCT02356315
View directory record Official record
Conditions
Neck Pain, Chronic Pain
Interventions
Functional Magnetic Resonance Imaging
Other
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 26, 2026, 8:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

AXER-204 in Participants With Chronic Spinal Cord Injury

NCT03989440
View directory record Official record
Conditions
Chronic Spinal Cord Injury
Interventions
AXER-204, Placebo
Drug
Lead sponsor
ReNetX Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 26, 2026, 8:16 AM EDT
Active, not recruiting Not applicable Interventional

Laying the Foundation for Building a Resilient KPNC Community in the Face of Worsening Air Quality Due to Wildfire Smoke

NCT07118189
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Exacerbation of COPD, Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions
N95 masks and indoor air cleaner
Device
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 26, 2026, 8:16 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT04783389
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
CBP-201, Placebo
Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
32
States / cities
Birmingham, Alabama • Bakersfield, California • La Mesa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 26, 2026, 8:16 AM EDT
Terminated Not applicable Interventional Results available

Developing a Pain Identification and Communication Toolkit

NCT03853291
View directory record Official record
Conditions
Dementia, Chronic Pain
Interventions
PICT Workbook, Information Pamphlet
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 100 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 26, 2026, 8:16 AM EDT
Completed Phase 3 Interventional

Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets

NCT03581591
View directory record Official record
Conditions
Hypophosphatemia, Hypophosphatemic Rickets, Pain, Chronic
Interventions
Burosumab
Biological
Lead sponsor
Redwood Dermatology Sciences
Other
Eligibility
Up to 18 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Clinton, Utah
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 26, 2026, 8:16 AM EDT
Completed Phase 1Phase 2 Interventional

A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C

NCT00246363
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Silymarin, Placebo
Drug
Lead sponsor
Henry Sacks
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Oct 26, 2026, 8:16 AM EDT
Completed Phase 3 Interventional Results available

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01316887
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
125/25 mcg once-daily GSK573719/GW642444, 125mcg once-daily GSK573719, Placebo once-daily
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 120 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
Mobile, Alabama • Sunset, Louisiana • Plymouth, Minnesota + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 26, 2026, 8:16 AM EDT